New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
EPIX Pharmaceuticals (EPIX)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
EPIX
»
Topics
»
5. Accrued Expenses
This excerpt taken from the
EPIX 10-K
filed Mar 11, 2005.
5. Accrued Expenses
Accrued expenses consist of the following:
December 31,
2004
2003
Accrued contractual product development expenses
$
2,330,849
$
3,000,088
Accrued compensation
969,925
1,654,702
Accrued intellectual property expenses
2,339,040
Other accrued expenses
918,060
865,029
$
4,218,834
$
7,858,859
"5. Accrued Expenses" elsewhere:
Anika Therapeutics (ANIK)
BioCryst Pharmaceuticals (BCRX)
Enzon Pharmaceuticals (ENZN)
GPC Biotech AG (GPCB)
Idenix Pharmaceuticals (IDIX)
IGI (IG)
Medarex (MEDX)
Micromet (MITI)
Matritech (MZT)
Biota Pharmaceuticals, Inc. (NABI)
Neose Technologies (NTEC)
ARCA biopharma, Inc. (NUVO)
Repligen (RGEN)
Tercica (TRCA)
Targacept (TRGT)
Vanda Pharmaceuticals (VNDA)
XenoPort (XNPT)
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour